BackNexien BioPharma Overview
Nexien BioPharma, Inc.

Nexien BioPharma Return on Equity

Nexien BioPharma (NXEN) has a ROE of 41.75%, above the sector sector average of 10.27%.

Get informed when a big investor buys or sells

+ Follow

ROE

41.75%

Return on Equity

41.75%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Nexien BioPharma (NXEN) FAQ

Nexien BioPharma posts a ROE of 41.75%. That is above the sector sector average of 10.27%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a ROE near 10.27% is typical. Nexien BioPharma's 41.75% is higher that level. That is roughly 306.7% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Nexien BioPharma's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 41.75%; use YoY and peer views to separate noise from signal.

Context for NXEN's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 10.27%), and (3) consistency with growth and profitability. This page covers the first two; Nexien BioPharma's other metric pages and overview cover the third.

Questions & Answers